INSTITUT CURIE;Centre National de la Recherche Scientifique (CNRS);Institut National de la Sante et da la Recherche Medicale (INSERM)
发明人:
Sebastian AMIGORENA,Eliane PIAGGIO,Christel GOUDOT,Luigia PACE,Genevieve ALMOUZNI
申请号：
US16425008
公开号：
US20190365807A1
申请日:
2019.05.29
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell； and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
